Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine For Travelers’ Diarrhea Stimulates Immune Response Even At Low Doses

Iomai Corporation (Nasdaq: IOMI) today announced results from a 400-patient, Phase 2 dose-ranging trial of its patch-based vaccine for travelers’ diarrhea. The trial was conducted to assess the ability of a range of vaccine doses to generate an immune response against enterotoxigenic E. coli (ETEC) bacteria — the most common cause of travelers’ diarrhea. [click link for full article]

Read More: continued here

Filed under: GastroIntestinal / Gastroentorology on May 7th, 2007